XOMA Corporation
$ 25.00
0.00%
07 Aug - close price
- Market Cap N/A
- Current Price $ 25.00
- High / Low $ 25.00 / 25.00
- Stock P/E 24.98
- Book Value 7.79
- EPS 1.00
- Next Earning Report f
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE 0.34 %
- 52 Week High 25.86
- 52 Week Low 23.18
About
XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and Asia Pacific. The company is headquartered in Emeryville, California.
Analyst Target Price
N/A
Quarterly Earnings
| Sep 2025 | Jun 2025 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 | Dec 2019 | Sep 2019 | Jun 2019 | Mar 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-15 | 2021-08-05 | 2021-05-06 | 2021-03-10 | 2020-11-05 | 2020-08-06 | 2020-05-05 | 2020-03-10 | 2019-11-05 | 2019-08-06 | 2019-05-06 |
| Reported EPS | 0.7 | 0.44 | -0.5131 | -0.3128 | -0.7031 | 1.5248 | -0.1 | -0.3264 | -0.4875 | -0.3847 | 0.2024 | -0.4667 |
| Estimated EPS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Surprise | 0.7 | 0.44 | -0.5131 | -0.3128 | -0.7031 | 1.5248 | -0.1 | -0.3264 | -0.4875 | -0.3847 | 0.2024 | -0.4667 |
| Surprise Percentage | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% |
Next Quarterly Earnings
| Aug 2026 | |
|---|---|
| Reported Date | f |
| Fiscal Date Ending | o |
| Estimated EPS | r |
| Currency | m |
Previous Dividend Records
| Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-07-14 | 2026-04-15 | 2026-01-15 | 2025-10-15 | 2025-07-15 | 2025-04-15 | 2025-01-15 | 2024-10-15 | 2024-07-15 | 2024-04-15 |
| Amount | $0.52344 | $0.52344 | $0.52344 | $0.52344 | $0.52344 | $0.52344 | $0.52344 | $0.52344 | $0.52344 | $0.52344 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: XOMAO
2026-08-05 18:14:23
Ligand Pharmaceuticals is set to report its second-quarter earnings, which will be the first financial update since its $739 million acquisition of XOMA Royalty Corporation. The report is crucial as analysts expect the deal to be immediately accretive to earnings, with projections of an additional $0.50 per share to 2026 and $1.50 per share to 2027 adjusted earnings. Investors will be closely watching management's commentary on the XOMA integration, the growth of Ligand's expanded royalty portfolio, and future capital deployment plans, especially after the company missed first-quarter estimates.
2026-08-03 18:09:32
This article provides an overview of XOMA Royalty Corporation's financial statements and key facts. The company operates as a biotech royalty aggregator, focusing on acquiring future economics from pre-commercial therapeutic candidates licensed to pharmaceutical or biotechnology companies. The article notes that there is currently no market capitalization, revenue, or net income data available, and the company has never paid dividends.
2026-07-30 01:51:24
This article provides a detailed financial overview of XOMA Royalty Corp (XOMA), including its income statement, balance sheet, and cash flow statement. It highlights recent earnings, revenue, EPS, and various financial indicators with year-over-year changes across multiple quarters and fiscal years. The content is presented in a data-rich dashboard format to facilitate financial analysis for investors.
2026-07-23 12:41:15
XOMA Royalty Corp filed an "EFFECT" form with the SEC, indicating a neutral impact and sentiment. The filing, accepted on July 23, 2026, details an effectiveness date of July 22, 2026, with accession number 0001193125-26-308937. This financial disclosure is part of the company's regular reporting requirements.
2026-07-21 02:40:52
XOMA Royalty LLC has filed a post-effective amendment to its Form S-3 shelf registration, originally covering $200 million in various securities, to remove all unsold securities from registration. This action follows a corporate restructuring, where XOMA Royalty Corporation converted to a Delaware limited liability company, and a subsequent merger where it became a wholly-owned subsidiary of Ligand Pharmaceuticals Incorporated. All offerings under the shelf registration have been terminated as a result of these changes.
2026-07-17 01:10:46
BVF-affiliated funds have tendered 7,593,303 shares of XOMA Royalty Corp (XOMA) common stock as part of Ligand Pharmaceuticals' cash merger, receiving $39.00 per share plus contingent value rights. This transaction, effective July 14, 2026, leaves no remaining holdings for these specific positions by the reporting persons. The move is a significant insider transaction reflecting the completion of the merger agreement.
